Faced with FDA barriers, 23andMe mulls overseas expansion

Personal genetics startup 23andMe is reportedly considering expanding overseas to so it can get sales back on track despite its standoff with the FDA. The Google ($GOOG)-backed business was hit with an FDA warning letter last year, after which it stopped providing an analysis of health risks with its test results. With the FDA slowing progress in the U.S., 23andMe is looking into whether Australia, Canada or the United Kingdom would be more amenable to its tests, Reuters reports. Article

Suggested Articles

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

Eric Perakslis' experience with Takeda will help facilitate a new collaboration between the two companies.